Ton N M Schumacher

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi request reprint Prospects and limitations of T cell receptor gene therapy
    Annelies Jorritsma
    The Netherlands Cancer Institute, Department of Immunology, Plesmanlaan, Amsterdam
    Curr Gene Ther 11:276-87. 2011
  2. pmc Intravital imaging of fluorescent markers and FRET probes by DNA tattooing
    Adriaan D Bins
    Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    BMC Biotechnol 7:2. 2007
  3. doi request reprint Mapping the life histories of T cells
    Ton N M Schumacher
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Immunol 10:621-31. 2010
  4. ncbi request reprint Requirements for effective antitumor responses of TCR transduced T cells
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:5128-36. 2008
  5. doi request reprint Generation of peptide MHC class I monomers and multimers through ligand exchange
    Mireille Toebes
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Protoc Immunol . 2009
  6. doi request reprint High-throughput T-cell epitope discovery through MHC peptide exchange
    Sine Reker Hadrup
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Methods Mol Biol 524:383-405. 2009
  7. pmc One naive T cell, multiple fates in CD8+ T cell differentiation
    Carmen Gerlach
    Division of Immunology, Central Microarray Facility, and Bioinformatics and Statistics Group, The Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
    J Exp Med 207:1235-46. 2010
  8. doi request reprint Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Med 16:565-70, 1p following 570. 2010
  9. doi request reprint Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer
    Gavin M Bendle
    Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    J Immunol 191:3232-9. 2013
  10. doi request reprint Heterogeneous differentiation patterns of individual CD8+ T cells
    Carmen Gerlach
    Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Science 340:635-9. 2013

Collaborators

Detail Information

Publications46

  1. ncbi request reprint Prospects and limitations of T cell receptor gene therapy
    Annelies Jorritsma
    The Netherlands Cancer Institute, Department of Immunology, Plesmanlaan, Amsterdam
    Curr Gene Ther 11:276-87. 2011
    ..Furthermore, we discuss the prospects of widespread clinical application of this gene therapy approach for the treatment of human cancer...
  2. pmc Intravital imaging of fluorescent markers and FRET probes by DNA tattooing
    Adriaan D Bins
    Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    BMC Biotechnol 7:2. 2007
    ..However, the generation of transgenic mice is a lengthy process and intravital imaging requires specialized knowledge and equipment. Here, we report a rapid and undemanding intravital imaging method using generally available equipment...
  3. doi request reprint Mapping the life histories of T cells
    Ton N M Schumacher
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Immunol 10:621-31. 2010
    ..Furthermore, we discuss the potential value of new technologies that would allow assessment of T cell migration patterns and prior signalling events...
  4. ncbi request reprint Requirements for effective antitumor responses of TCR transduced T cells
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:5128-36. 2008
    ..The strategies outlined in this study should be of value to enhance the antitumor activity of TCR-modified T cells in clinical trials...
  5. doi request reprint Generation of peptide MHC class I monomers and multimers through ligand exchange
    Mireille Toebes
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Protoc Immunol . 2009
    ..This technology is based on the development of conditional MHC ligands that can be triggered to self-destruct while in the MHC-bound state...
  6. doi request reprint High-throughput T-cell epitope discovery through MHC peptide exchange
    Sine Reker Hadrup
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Methods Mol Biol 524:383-405. 2009
    ..These high-throughput assays should prove valuable for the screening of entire disease-associated proteomes, including pathogen-encoded proteomes, tumor-associated antigens, and autoimmune antigens...
  7. pmc One naive T cell, multiple fates in CD8+ T cell differentiation
    Carmen Gerlach
    Division of Immunology, Central Microarray Facility, and Bioinformatics and Statistics Group, The Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
    J Exp Med 207:1235-46. 2010
    ..Instead, for both low and high avidity T cells, individual naive T cells have multiple fates and can differentiate into effector and memory T cell subsets...
  8. doi request reprint Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Med 16:565-70, 1p following 570. 2010
    ..Furthermore, we demonstrate that adjustments in the design of gene therapy vectors and target T cell populations can be used to reduce the risk of TCR gene therapy-induced autoimmune pathology...
  9. doi request reprint Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer
    Gavin M Bendle
    Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    J Immunol 191:3232-9. 2013
    ....
  10. doi request reprint Heterogeneous differentiation patterns of individual CD8+ T cells
    Carmen Gerlach
    Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Science 340:635-9. 2013
    ....
  11. pmc Development of a hypersensitive periodate-cleavable amino acid that is methionine- and disulfide-compatible and its application in MHC exchange reagents for T cell characterisation
    Alessia Amore
    Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Chembiochem 14:123-31. 2013
    ..Conditional MHC reagents hypersensitive to periodate can now be applied without limitations when UV irradiation is undesired or less practical...
  12. ncbi request reprint Prospects and limitations of T cell receptor gene therapy
    Miriam Coccoris
    The Netherlands Cancer Institute, Department of Immunology, Amsterdam, The Netherlands
    Curr Gene Ther 5:583-93. 2005
    ..Furthermore, we discuss the prospects of clinical application of this gene therapy approach, and the possible barriers on the route towards clinical use...
  13. doi request reprint High-throughput identification of antigen-specific TCRs by TCR gene capture
    Carsten Linnemann
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Med 19:1534-41. 2013
    ....
  14. pmc TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 181:2563-71. 2008
    ..These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells...
  15. doi request reprint The descent of memory T cells
    Carmen Gerlach
    The Netherlands Cancer Institute, Department of Immunology, Amsterdam, The Netherlands
    Ann N Y Acad Sci 1217:139-53. 2011
    ....
  16. doi request reprint Preclinical development of T cell receptor gene therapy
    Gavin M Bendle
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Immunol 21:209-14. 2009
    ..Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials...
  17. doi request reprint T-cell receptor gene therapy: critical parameters for clinical success
    Carsten Linnemann
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Invest Dermatol 131:1806-16. 2011
    ..This review highlights those strategies that can be followed to develop TCR gene therapy into a clinically relevant treatment option for cancer patients...
  18. ncbi request reprint T-cell-receptor gene therapy
    Ton N M Schumacher
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Nat Rev Immunol 2:512-9. 2002
    ..In this review, I discuss the pros and cons of TCR gene transfer as a strategy to induce defined virus- and tumour-specific T-cell immunity...
  19. doi request reprint Microbead-assisted retroviral transduction for clinical application
    Bianca Heemskerk
    Department of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    Hum Gene Ther 21:1335-42. 2010
    ..Viral coating of microbeads should facilitate the production of genetically modified cells, in particular for use in clinical trials...
  20. doi request reprint Immunotherapeutic strategies: the melanoma example
    Annelies Jorritsma
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Immunotherapy 1:679-90. 2009
    ..Although TCR gene transfer has, until now, only resulted in a low frequency of clinical responses, it does have a broader application potential, and optimization of this strategy is likely to improve its efficacy...
  21. ncbi request reprint Targeting self-antigens through allogeneic TCR gene transfer
    Moniek A de Witte
    Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Blood 108:870-7. 2006
    ....
  22. doi request reprint HLA Micropolymorphisms Strongly Affect Peptide-MHC Multimer-Based Monitoring of Antigen-Specific CD8+ T Cell Responses
    Marit M van Buuren
    Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    J Immunol 192:641-8. 2014
    ....
  23. pmc The cancer antigenome
    Bianca Heemskerk
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    EMBO J 32:194-203. 2013
    ..Furthermore, the description of the cancer antigenome should form the basis of novel forms of personalized cancer immunotherapy...
  24. ncbi request reprint Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
    Annelies Jorritsma
    Department of Immunology, The Netherlands Cancer Institute NKI, Amsterdam, The Netherlands
    Blood 110:3564-72. 2007
    ..The procedures described in this study should be of general value for the selection of well- and stably expressed, high-affinity, and safe human TCRs for subsequent clinical testing...
  25. doi request reprint Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer
    Annelies Jorritsma
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Res 68:2455-62. 2008
    ..This strategy does not require ex vivo expansion of cells to generate effective antitumor immunity and may therefore easily be translated to clinical application...
  26. ncbi request reprint An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    J Immunol 180:6365-73. 2008
    ..These data provide strong support for the evaluation of this conditional safety switch in clinical trials of adoptive cell therapy...
  27. ncbi request reprint Adoptive transfer of T-cell immunity
    Helmut W H G Kessels
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Trends Immunol 23:264-9. 2002
  28. doi request reprint TCR repertoires of intratumoral T-cell subsets
    Carsten Linnemann
    Division of Immunology, The Netherlands Cancer Institute NKI AvL, Amsterdam, The Netherlands
    Immunol Rev 257:72-82. 2014
    ....
  29. doi request reprint Class I major histocompatibility complexes loaded by a periodate trigger
    Boris Rodenko
    Division of Cell Biology II, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Am Chem Soc 131:12305-13. 2009
    ..In addition, this technology will be useful to develop miniaturized assay systems for performing high-throughput screens for natural and unnatural MHC ligands...
  30. ncbi request reprint Long-term functionality of TCR-transduced T cells in vivo
    Miriam Coccoris
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunol 180:6536-43. 2008
    ..These experiments indicate that TCR gene transfer can be used to generate long-term Ag-specific T cell responses and provide a useful model system to assess the factors that can promote high-level persistence of TCR-modified T cells...
  31. ncbi request reprint Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?
    Tanina A Cordaro
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunol 168:651-60. 2002
    ..c. growing tumors. Together, these findings indicate that, when only a low-avidity repertoire is available to generate antitumor immunity, the best strategy may be to enhance memory responses...
  32. ncbi request reprint Optimizing the efficacy of epitope-directed DNA vaccination
    Monika C Wolkers
    Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Immunol 168:4998-5004. 2002
    ..Moreover, T cell immunity induced by this type of optimized DNA vaccine provides long-term protection against otherwise lethal tumor challenges...
  33. ncbi request reprint Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice
    Natascha C V Verra
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Res 64:2153-61. 2004
    ....
  34. ncbi request reprint CD8+ T cell tolerance and cancer immunotherapy
    Karin E de Visser
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunother 26:1-11. 2003
    ..Furthermore, the authors discuss the influence of negative selection on the antitumor reactivity of the mature T cell repertoire...
  35. ncbi request reprint Gene transfer of MHC-restricted receptors
    Helmut W H G Kessels
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Methods Mol Med 109:201-14. 2005
    ..Here we discuss the requirements for the successful genetic modification of murine T-lymphocytes and the subsequent use of such genetically modified cells in in vivo models...
  36. ncbi request reprint Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas
    Koen Schepers
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunol 169:3191-9. 2002
    ....
  37. ncbi request reprint The impact of self-tolerance on the polyclonal CD8+ T cell repertoire
    Helmut W H G Kessels
    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunol 172:2324-31. 2004
    ..Thus, while individual T cells are markedly cross-reactive, the ability to distinguish between closely related Ags is introduced at the polyclonal T cell level...
  38. ncbi request reprint Antigen bias in T cell cross-priming
    Monika C Wolkers
    Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    Science 304:1314-7. 2004
    ..Such differences in the ability to cross-present antigens should form important considerations in vaccine design...
  39. ncbi request reprint A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression
    Adriaan D Bins
    Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Nat Med 11:899-904. 2005
    ..The strength and speed of this newly developed strategy will be beneficial in situations in which immunity is required in the shortest possible time...
  40. ncbi request reprint MHC multimer technology: current status and future prospects
    Arnold H Bakker
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Curr Opin Immunol 17:428-33. 2005
    ..Furthermore, recent work demonstrates the potential of high-throughput detection of T cell responses and suggests that manipulation of T cell responses through the use of multimeric MHC reagents is also feasible...
  41. ncbi request reprint Design and use of conditional MHC class I ligands
    Mireille Toebes
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Nat Med 12:246-51. 2006
    ..We document the value of this approach by identifying cytotoxic T-cell epitopes within the H5N1 influenza A/Vietnam/1194/04 genome...
  42. ncbi request reprint Generation of T cell help through a MHC class I-restricted TCR
    Helmut W H G Kessels
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, CX 1066 Amsterdam, The Netherlands
    J Immunol 177:976-82. 2006
    ..The ability to generate Th cell immunity by infusion of MHC class I-restricted Th cells may prove useful for the induction of tumor-specific T cell immunity in cases where MHC class II-associated epitopes are lacking...
  43. ncbi request reprint Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease
    Moniek A de Witte
    Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Blood 109:3830-8. 2007
    ..These data indicate that antigen-specific graft engineering is feasible, but that parameters other than immunodominance may be required to select T-cell specificities that are targeted for removal...
  44. ncbi request reprint In vivo antigen stability affects DNA vaccine immunogenicity
    Adriaan D Bins
    Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Immunol 179:2126-33. 2007
    ....
  45. ncbi request reprint Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors
    Anja U van Lent
    Department of Cell Biology and Histology, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 179:4959-68. 2007
    ..Therapeutic applications may arise from these results because they provide a way to produce large numbers of autologous mature Ag-specific T cells in vitro from undifferentiated hemopoietic progenitors...
  46. doi request reprint Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient
    Jeroen W J van Heijst
    Department of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    Science 325:1265-9. 2009
    ..Thus, naïve T cell recruitment is highly efficient, and the magnitude of antigen-specific CD8+ T cell responses is primarily controlled by clonal expansion...